Buchet J P, Geubel A, Pauwels S, Mahieu P, Lauwerys R
Arch Toxicol. 1984 Sep;55(3):151-4. doi: 10.1007/BF00316119.
The capacity for inorganic arsenic (ASi) methylation in 13 healthy volunteers and in 30 patients with different types of liver disease has been assessed by measuring the amount of unmetabolized ASi, monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) excreted in urine within 24 h after the IV injection of 7.14 micrograms/kg ASi. Liver disease does not affect the percent of the injected dose excreted within 24 h but has striking and opposite effects on the proportions of MMA and DMA. MMA excretion is highly correlated with the 14C-aminopyrine breath test (r = 0.73; P less than 0.05). The reduction in the proportion of MMA excreted in urine and the increase in that of DMA are similar with regard to sensitivity and specificity for detecting liver impairment. Unlike the 14C-aminopyrine breath test, the inorganic arsenic methylation test offers the advantage of being unaffected by treatment with microsomal enzyme inducers.
通过静脉注射7.14微克/千克无机砷（ASi）后，测量24小时内尿液中排泄的未代谢ASi、一甲基胂酸（MMA）和二甲基胂酸（DMA）的量，评估了13名健康志愿者和30名不同类型肝病患者的无机砷（ASi）甲基化能力。肝病不影响24小时内排泄的注射剂量百分比，但对MMA和DMA的比例有显著且相反的影响。MMA排泄与14C-氨基比林呼气试验高度相关（r = 0.73；P < 0.05）。尿液中排泄的MMA比例降低和DMA比例增加在检测肝功能损害的敏感性和特异性方面相似。与14C-氨基比林呼气试验不同，无机砷甲基化试验具有不受微粒体酶诱导剂治疗影响的优点。
